샤르코 마리 투스병 신규 치료법 보고서(2026년)(2분기판)

The Global Charcot-Marie-Tooth Disease Emerging Therapies Market is projected to grow from USD 0.94 billion 2026 at a CAGR of 70.6% to USD 13.60 billion in 2031.

The global Charcot-Marie-Tooth (CMT) disease emerging therapies market is entering a transformative phase as advances in molecular genetics, gene therapy, RNA-based therapeutics, and precision medicine accelerate the development of disease-modifying treatments. Emerging therapies analysis provides comprehensive insights into investigational products, therapeutic mechanisms, clinical development progress, regulatory designations, licensing activities, technology platforms, and commercialization opportunities. As the understanding of the molecular pathways responsible for inherited peripheral neuropathies continues to improve, developers are increasingly focusing on therapies that target the underlying genetic causes of disease rather than providing only symptomatic relief.

Charcot-Marie-Tooth disease is a genetically heterogeneous group of inherited peripheral neuropathies caused by mutations affecting peripheral nerve myelination and axonal integrity. Conventional treatment remains largely supportive, relying on rehabilitation, orthotic devices, pain management, and physical therapy. The absence of approved disease-modifying therapies for most CMT subtypes has created substantial opportunities for innovation. Current emerging therapies include gene replacement technologies, antisense oligonucleotides, RNA interference therapies, HDAC6 inhibitors, small molecules, regenerative medicine approaches, and neuroprotective agents designed to slow disease progression or restore nerve function.

Rapid advances in genetic sequencing, biomarker discovery, artificial intelligence-assisted drug discovery, and decentralized clinical trials are improving the efficiency of therapeutic development. Improved genetic diagnosis enables more accurate patient stratification, while international patient registries and natural history studies support recruitment for mutation-specific clinical trials. These developments are strengthening clinical evidence generation and accelerating translation from laboratory research to clinical development.

Strategic collaborations between pharmaceutical companies, biotechnology innovators, academic research institutions, contract research organizations, and patient advocacy groups continue to expand the therapeutic ecosystem. Regulatory incentives for orphan diseases, increasing venture capital investment, and growing interest in precision neurology are expected to support continued innovation throughout the forecast period. As multiple investigational therapies progress through clinical evaluation, emerging treatments are expected to reshape the future management of Charcot-Marie-Tooth disease.

Market Drivers

Advancements in Gene and RNA Therapeutics

Gene replacement therapies, gene silencing technologies, antisense oligonucleotides, and RNA interference platforms are driving the next generation of CMT treatment development.

These technologies seek to address disease progression by correcting or suppressing disease-causing genetic abnormalities.

Growing Investment in Rare Neurological Diseases

Pharmaceutical companies and biotechnology firms continue increasing investment in inherited neurological disorders with significant unmet clinical needs.

Growing financial support is accelerating discovery research, translational medicine, and clinical development.

Expansion of Precision Medicine

Improved genetic diagnostics enable mutation-specific therapeutic development and personalized treatment strategies.

Precision medicine continues to improve patient selection while increasing the probability of successful clinical outcomes.

Technological Innovation in Drug Discovery

Artificial intelligence, computational biology, biomarker discovery, and digital clinical research platforms are improving target identification and therapeutic optimization.

These innovations reduce development timelines while supporting more efficient clinical trials.

Supportive Regulatory Environment

Orphan drug incentives, expedited regulatory pathways, and increasing government support for rare diseases continue encouraging investment in innovative CMT therapies.

These initiatives improve commercialization opportunities while reducing development barriers.

Market Restraints

Extensive Genetic Heterogeneity

More than one hundred genetic mutations have been associated with Charcot-Marie-Tooth disease, creating significant challenges for broad therapeutic development.

Many investigational therapies must be tailored to specific genetic subtypes.

High Development Costs

Gene therapies, RNA therapeutics, and advanced biologics require substantial investment in research, manufacturing, regulatory compliance, and long-term clinical evaluation.

Development costs remain a significant challenge, particularly for smaller biotechnology companies.

Clinical Development Complexity

Slow disease progression, limited patient populations, and the need for sensitive biomarkers complicate clinical trial design and efficacy assessment.

These factors may extend development timelines and increase operational risk.

Technology and Segment Insights

By Therapy Type

Gene therapies represent one of the fastest-growing segments because they directly target disease-causing genetic abnormalities.

RNA therapeutics, antisense oligonucleotides, small molecules, HDAC6 inhibitors, regenerative medicine platforms, and neuroprotective agents continue expanding the emerging therapeutic landscape.

By Development Stage

Preclinical and Phase I programs account for a substantial portion of emerging therapies as developers evaluate innovative molecular technologies.

Phase II clinical studies continue expanding as promising candidates demonstrate encouraging safety and efficacy profiles, while selected late-stage programs advance toward regulatory evaluation.

By Mechanism of Action

Emerging therapies increasingly target PMP22 gene expression, Schwann cell biology, axonal regeneration, mitochondrial dysfunction, neuroprotection, inflammatory pathways, and mutation-specific molecular mechanisms.

These approaches aim to slow disease progression while preserving peripheral nerve function.

By End User

Pharmaceutical companies remain the primary developers of emerging therapies through sustained investment in rare neurological disorders.

Biotechnology firms contribute innovative genetic platforms and precision medicine technologies, while academic institutions and contract research organizations support translational research and multicenter clinical studies.

Regional Insights

North America dominates the emerging therapies landscape owing to advanced biotechnology infrastructure, extensive venture capital investment, established regulatory pathways, and strong expertise in rare neurological disorders. The United States continues to lead innovation in gene therapy, precision medicine, and multinational clinical research.

Europe represents another major innovation hub supported by specialized neuromuscular research centers, collaborative academic networks, and strong pharmaceutical capabilities. Germany, the United Kingdom, France, Italy, Spain, and the Netherlands continue contributing significantly to therapeutic innovation and clinical development.

Asia Pacific is expected to experience the fastest growth during the forecast period owing to expanding biotechnology investment, improving genetic testing infrastructure, supportive government initiatives, and increasing participation in international clinical trials across China, Japan, South Korea, India, and Australia.

Latin America and the Middle East & Africa are gradually strengthening research capabilities through healthcare modernization, international collaborations, and growing participation in rare disease development programs.

Competitive and Strategic Outlook

The global Charcot-Marie-Tooth disease emerging therapies market is characterized by active participation from multinational pharmaceutical companies, biotechnology innovators, academic research institutions, and specialized neuromuscular disease developers. Competition increasingly focuses on developing disease-modifying therapies capable of correcting underlying genetic abnormalities, slowing disease progression, and improving long-term neurological outcomes.

Organizations continue investing in gene therapy, RNA therapeutics, HDAC6 inhibitors, biomarker discovery, artificial intelligence-assisted drug development, and precision medicine platforms. Strategic licensing agreements, research collaborations, acquisitions, venture financing, and co-development partnerships continue accelerating innovation while strengthening competitive positioning. The increasing diversity of investigational therapeutic approaches reflects growing confidence in the long-term commercial potential of the CMT treatment landscape.

Conclusion

The global Charcot-Marie-Tooth disease emerging therapies market is expected to experience sustained growth as advances in genetics, molecular medicine, and precision neurology continue transforming therapeutic development. Increasing investment in rare neurological disorders, expanding gene and RNA therapy pipelines, supportive regulatory initiatives, and growing collaboration across the biotechnology ecosystem are expected to drive innovation throughout the forecast period. Although challenges related to genetic complexity, patient recruitment, and development costs remain, continued scientific progress is expected to accelerate the introduction of effective disease-modifying therapies that improve long-term outcomes for individuals living with Charcot-Marie-Tooth disease.

Key Benefits of this Report

• Insightful Analysis: Detailed market insights across regions, customer segments, policies, socio-economic factors, consumer preferences, and industry verticals.
• Competitive Landscape: Understand strategic moves by key players to identify optimal market entry approaches.
• Market Drivers and Future Trends: Assess major growth forces and emerging developments shaping the market.
• Actionable Recommendations: Support strategic decisions to unlock new revenue streams.
• Caters to a Wide Audience: Suitable for startups, research institutions, consultants, SMEs, and large enterprises.

What Businesses Use Our Reports For

Industry and market insights, opportunity assessment, product demand forecasting, market entry strategy, geographical expansion, capital investment decisions, regulatory analysis, new product development, and competitive intelligence.

Report Coverage

• Historical data from 2021 to 2024, Base year 2025, and Forecast years from 2026 to 2031
• Growth opportunities, challenges, supply chain outlook, regulatory framework, and trend analysis
• Competitive positioning, strategies, and market share evaluation, and trade analysis
• Revenue growth and forecast assessment across segments and regions
• Company profiling including strategies, products, financials, and key developments

TABLE OF CONTENTS

1. Executive Summary

• 1.1 Report Scope and Objectives
  • 1.1.1 Emerging Therapy Landscape Overview
  • 1.1.2 Scope of Pipeline Intelligence Assessment
  • 1.1.3 Research Methodology Summary
  • 1.1.4 Key Strategic Findings
• 1.2 Executive Insights
  • 1.2.1 Emerging Therapy Development Trends
  • 1.2.2 Innovation Hotspots
  • 1.2.3 High-Potential Pipeline Assets
  • 1.2.4 Competitive Intelligence Highlights
  • 1.2.5 Future Treatment Paradigm Outlook
• 1.3 Key Conclusions
  • 1.3.1 Most Advanced Emerging Therapies
  • 1.3.2 Novel Mechanism Leaders
  • 1.3.3 Regulatory Milestones to Watch
  • 1.3.4 Commercial Opportunity Summary

2. Pipeline Overview

• 2.1 Charcot-Marie-Tooth Disease Emerging Therapy Landscape
  • 2.1.1 Historical Evolution of Therapeutic Development
  • 2.1.2 Current Pipeline Maturity Assessment
  • 2.1.3 Emerging Therapy Development Trends
  • 2.1.4 Innovation Intensity Analysis
• 2.2 Pipeline Distribution by Development Phase
  • 2.2.1 Preclinical Stage Assets
    • 2.2.1.1 Number of Assets
    • 2.2.1.2 Technology Platforms
    • 2.2.1.3 Emerging Developers
  • 2.2.2 Phase I Assets
    • 2.2.2.1 Number of Assets
    • 2.2.2.2 Safety Evaluation Programs
    • 2.2.2.3 Early Clinical Signals
  • 2.2.3 Phase II Assets
    • 2.2.3.1 Number of Assets
    • 2.2.3.2 Proof-of-Concept Programs
    • 2.2.3.3 Mid-Stage Competitive Benchmarking
  • 2.2.4 Phase III Assets
    • 2.2.4.1 Number of Assets
    • 2.2.4.2 Pivotal Trial Programs
    • 2.2.4.3 Registration Readiness
  • 2.2.5 Filed / Under Regulatory Review Assets
    • 2.2.5.1 Submission Status
    • 2.2.5.2 Regulatory Review Milestones
    • 2.2.5.3 Approval Probability Assessment
• 2.3 Historical Progression Trends
  • 2.3.1 Pipeline Growth by Year
  • 2.3.2 Clinical Advancement Patterns
  • 2.3.3 Historical Attrition Analysis
  • 2.3.4 Regulatory Success Trends

3. Disease and Unmet Need Analysis

• 3.1 Disease Overview
  • 3.1.1 Disease Definition and Classification
  • 3.1.2 Genetic Architecture
  • 3.1.3 Pathophysiology and Disease Progression
  • 3.1.4 Clinical Burden Assessment
• 3.2 Disease Subtype Assessment
  • 3.2.1 Charcot-Marie-Tooth Type 1
  • 3.2.2 Charcot-Marie-Tooth Type 2
  • 3.2.3 Charcot-Marie-Tooth Type 4
  • 3.2.4 X-Linked Charcot-Marie-Tooth Disease
  • 3.2.5 Rare Genetic Variants
• 3.3 Existing Treatment Landscape
  • 3.3.1 Symptomatic Management Approaches
  • 3.3.2 Physical and Occupational Therapy
  • 3.3.3 Orthotic and Assistive Interventions
  • 3.3.4 Surgical Management
  • 3.3.5 Limitations of Current Standard of Care
• 3.4 Unmet Clinical Needs
  • 3.4.1 Lack of Disease-Modifying Therapies
  • 3.4.2 Genetic Subtype-Specific Treatment Gaps
  • 3.4.3 Functional Outcome Limitations
  • 3.4.4 Long-Term Disease Management Challenges
• 3.5 Emerging Therapy Opportunities
  • 3.5.1 Precision Medicine Opportunities
  • 3.5.2 Gene Therapy Opportunities
  • 3.5.3 RNA-Based Therapeutic Opportunities
  • 3.5.4 Regenerative Medicine Opportunities

4. Mechanism and Modality Landscape

• 4.1 Mechanism of Action Landscape
  • 4.1.1 PMP22 Gene Regulation Approaches
    • 4.1.1.1 Scientific Rationale
    • 4.1.1.2 Pipeline Activity
    • 4.1.1.3 Competitive Assessment
  • 4.1.2 Gene Replacement Strategies
    • 4.1.2.1 Target Genetic Subtypes
    • 4.1.2.2 Technology Platforms
    • 4.1.2.3 Development Challenges
  • 4.1.3 RNA Therapeutic Approaches
    • 4.1.3.1 Antisense Oligonucleotides
    • 4.1.3.2 RNA Interference Technologies
    • 4.1.3.3 Delivery Platform Innovations
  • 4.1.4 Neuroprotective Therapies
  • 4.1.5 Axonal Regeneration Strategies
  • 4.1.6 Schwann Cell Modulation Approaches
  • 4.1.7 Neuromuscular Function Enhancement
• 4.2 Mechanism Clustering Analysis
  • 4.2.1 Asset Distribution by Mechanism
  • 4.2.2 Competitive Density Assessment
  • 4.2.3 White Space Opportunities
  • 4.2.4 Mechanism-Based Risk Evaluation
• 4.3 Innovation Assessment
  • 4.3.1 First-in-Class Therapy Candidates
  • 4.3.2 Best-in-Class Therapy Candidates
  • 4.3.3 Breakthrough Innovation Opportunities
  • 4.3.4 Emerging Scientific Trends
• 4.4 Modality Analysis
  • 4.4.1 Small Molecules
  • 4.4.2 Biologics
  • 4.4.3 RNA Therapeutics
  • 4.4.4 Gene Therapies
  • 4.4.5 Cell-Based Therapies

5. Clinical Development Intelligence

• 5.1 Clinical Trial Landscape
  • 5.1.1 Active Trials
  • 5.1.2 Recruiting Trials
  • 5.1.3 Completed Trials
  • 5.1.4 Suspended and Terminated Trials
  • 5.1.5 Historical Trial Activity Trends
• 5.2 Trial Design Benchmarking
  • 5.2.1 Study Design Comparison
  • 5.2.2 Randomization Strategies
  • 5.2.3 Comparator Selection
  • 5.2.4 Blinding Methodologies
• 5.3 Endpoint Intelligence
  • 5.3.1 Functional Endpoints
  • 5.3.2 Neurological Assessment Measures
  • 5.3.3 Biomarker Utilization
  • 5.3.4 Quality-of-Life Assessments
  • 5.3.5 Digital Endpoint Integration
• 5.4 Recruitment Intelligence
  • 5.4.1 Sample Size Benchmarking
  • 5.4.2 Recruitment Performance Analysis
  • 5.4.3 Enrollment Timelines
  • 5.4.4 Registry-Supported Recruitment
  • 5.4.5 Geographic Enrollment Trends
• 5.5 Success and Failure Intelligence
  • 5.5.1 Clinical Success Factors
  • 5.5.2 Failure Pattern Analysis
  • 5.5.3 Dropout Trend Assessment
  • 5.5.4 Development Risk Drivers

6. Pipeline Segmentation Analysis

• 6.1 Pipeline by Development Phase
  • 6.1.1 Preclinical Assets
  • 6.1.2 Phase I Assets
  • 6.1.3 Phase II Assets
  • 6.1.4 Phase III Assets
  • 6.1.5 Filed / Under Review Assets
• 6.2 Pipeline by Mechanism of Action
  • 6.2.1 Gene Regulation Therapies
  • 6.2.2 RNA Therapeutics
  • 6.2.3 Gene Replacement Therapies
  • 6.2.4 Neuroprotective Therapies
  • 6.2.5 Regenerative Therapies
• 6.3 Pipeline by Therapeutic Modality
  • 6.3.1 Small Molecule Therapies
  • 6.3.2 Biologic Therapies
  • 6.3.3 RNA Therapeutics
  • 6.3.4 Gene Therapies
  • 6.3.5 Cell-Based Therapies

7. Probability of Success and Risk Analysis

• 7.1 Phase Transition Probability Modeling
  • 7.1.1 Preclinical-to-Phase I Transition
  • 7.1.2 Phase I-to-Phase II Transition
  • 7.1.3 Phase II-to-Phase III Transition
  • 7.1.4 Phase III-to-Approval Transition
• 7.2 Attrition Analysis
  • 7.2.1 Attrition by Phase
  • 7.2.2 Attrition by Mechanism
  • 7.2.3 Attrition by Modality
  • 7.2.4 Historical Attrition Benchmarking
• 7.3 Risk Assessment Framework
  • 7.3.1 Scientific Risk Assessment
  • 7.3.2 Clinical Risk Assessment
  • 7.3.3 Regulatory Risk Assessment
  • 7.3.4 Commercial Risk Assessment
• 7.4 Risk-Adjusted Pipeline Valuation
  • 7.4.1 Asset-Level Probability Weighting
  • 7.4.2 Portfolio-Level Risk Assessment
  • 7.4.3 Probability-Weighted Revenue Potential
  • 7.4.4 Scenario-Based Forecasting

8. Launch Timeline and Commercial Potential

• 8.1 Regulatory Forecasting
  • 8.1.1 Submission Timeline Forecasts
  • 8.1.2 Approval Timeline Forecasts
  • 8.1.3 Key Regulatory Milestones
• 8.2 Launch Sequencing Analysis
  • 8.2.1 First-to-Market Opportunities
  • 8.2.2 Follow-On Entrant Analysis
  • 8.2.3 Competitive Launch Scenarios
• 8.3 Commercial Potential Assessment
  • 8.3.1 Addressable Patient Population
  • 8.3.2 Adoption Curve Assessment
  • 8.3.3 Pricing and Access Considerations
  • 8.3.4 Peak Sales Opportunity Analysis
• 8.4 Future Treatment Paradigm Impact
  • 8.4.1 Precision Medicine Impact
  • 8.4.2 Gene Therapy Impact
  • 8.4.3 RNA Therapy Market Impact
  • 8.4.4 Long-Term Standard-of-Care Evolution

9. Competitive Pipeline Landscape

• 9.1 Competitive Positioning Framework
  • 9.1.1 Company Ranking Methodology
  • 9.1.2 Pipeline Strength Assessment
  • 9.1.3 Innovation Leadership Analysis
  • 9.1.4 Competitive Benchmark Matrix
• 9.2 Company-Wise Emerging Therapy Landscape
  • 9.2.1 Leading Developers
  • 9.2.2 Emerging Biotechnology Companies
  • 9.2.3 Academic Research Contributors
  • 9.2.4 Collaborative Development Networks
• 9.3 Asset-Level Emerging Therapy Intelligence
  • 9.3.1 Emerging Therapy Asset Profiles
    • 9.3.1.1 Molecule Overview
    • 9.3.1.2 Developer Company
    • 9.3.1.3 Mechanism of Action
    • 9.3.1.4 Development Phase
    • 9.3.1.5 Target Indication
    • 9.3.1.6 Clinical Trial Status
    • 9.3.1.7 Competitive Differentiation
    • 9.3.1.8 Probability of Success Assessment
• 9.4 Competitive Dynamics
  • 9.4.1 Leader vs Challenger Assessment
  • 9.4.2 Innovation Competition Analysis
  • 9.4.3 Strategic Positioning Matrix
  • 9.4.4 Future Competitive Outlook

10. Geographic Analysis

• 10.1 North America
  • 10.1.1 Clinical Trial Activity
  • 10.1.2 Regulatory Speed
  • 10.1.3 Innovation Hubs
  • 10.1.4 Emerging Therapy Development Activity
• 10.2 Europe
  • 10.2.1 Clinical Trial Activity
  • 10.2.2 Regulatory Speed
  • 10.2.3 Innovation Hubs
  • 10.2.4 Emerging Therapy Development Activity
• 10.3 Asia-Pacific
  • 10.3.1 Clinical Trial Activity
  • 10.3.2 Regulatory Speed
  • 10.3.3 Innovation Hubs
  • 10.3.3 Emerging Therapy Development Activity
• 10.4 Latin America
  • 10.4.1 Clinical Trial Activity
  • 10.4.2 Regulatory Speed
  • 10.4.3 Innovation Hubs
  • 10.4.4 Emerging Therapy Development Activity
• 10.5 Middle East & Africa
  • 10.5.1 Clinical Trial Activity
  • 10.5.2 Regulatory Speed
  • 10.5.3 Innovation Hubs
  • 10.5.4 Emerging Therapy Development Activity

11. Key Countries Analysis

• 11.1 United States
  • 11.1.1 Trial Activity
  • 11.1.2 Regulatory Timelines
  • 11.1.3 Key Sponsors
  • 11.1.4 Emerging Therapy Ecosystem
• 11.2 Canada
  • 11.2.1 Trial Activity
  • 11.2.2 Regulatory Timelines
  • 11.2.3 Key Sponsors
  • 11.2.4 Emerging Therapy Ecosystem
• 11.3 Germany
• 11.4 United Kingdom
• 11.5 France
• 11.6 Italy
• 11.7 Spain
• 11.8 China
• 11.9 Japan
• 11.10 India
• 11.11 South Korea
• 11.12 Australia
• 11.13 Brazil
• 11.14 Mexico
• 11.15 Saudi Arabia
• 11.16 South Africa

12. Deals and Investment Landscape

• 12.1 Licensing Agreements
  • 12.1.1 Asset Licensing Activity
  • 12.1.2 Technology Platform Licensing
  • 12.1.3 Regional Commercialization Agreements
• 12.2 Co-Development Partnerships
  • 12.2.1 Industry Collaborations
  • 12.2.2 Academic Partnerships
  • 12.2.3 Research Consortium Participation
• 12.3 Mergers and Acquisitions
  • 12.3.1 Asset Acquisitions
  • 12.3.2 Company Acquisitions
  • 12.3.3 Strategic Consolidation Trends
• 12.4 Funding Landscape
  • 12.4.1 Venture Capital Funding
  • 12.4.2 Private Equity Activity
  • 12.4.3 Public Financing Events
  • 12.4.4 Rare Disease Grant Funding
• 12.5 Investment Intelligence
  • 12.5.1 Investment by Modality
  • 12.5.2 Investment by Development Stage
  • 12.5.3 Capital Deployment Trends
  • 12.5.4 Future Funding Outlook

13. Future Outlook and Strategic Insights

• 13.1 Future Emerging Therapy Landscape
  • 13.1.1 Next-Generation Gene Therapies
  • 13.1.2 Advanced RNA Therapeutics
  • 13.1.3 Regenerative Medicine Evolution
  • 13.1.4 Precision Medicine Transformation
• 13.2 Competitive Outlook
  • 13.2.1 Future Market Leaders
  • 13.2.2 Emerging Challengers
  • 13.2.3 Competitive Threat Assessment
  • 13.2.4 Strategic Advantage Drivers
• 13.3 Strategic Opportunity Analysis
  • 13.3.1 White Space Opportunities
  • 13.3.2 Partnership Opportunities
  • 13.3.3 Geographic Expansion Opportunities
  • 13.3.4 Platform Technology Opportunities
• 13.4 Long-Term Forecast
  • 13.4.1 Five-Year Emerging Therapy Outlook
  • 13.4.2 Ten-Year Innovation Outlook
  • 13.4.3 Future Standard-of-Care Transformation

14. Methodology and Data Framework

• 14.1 Research Methodology
  • 14.1.1 Primary Research Sources
  • 14.1.2 Secondary Research Sources
  • 14.1.3 Data Validation Process
• 14.2 Asset Verification Framework
  • 14.2.1 ClinicalTrials.gov Verification
  • 14.2.2 EU Clinical Trials Register Verification
  • 14.2.3 Company Pipeline Validation
  • 14.2.4 Regulatory Filing Validation
• 14.3 Competitive Intelligence Methodology
  • 14.3.1 Company Benchmarking Framework
  • 14.3.2 Asset Ranking Methodology
  • 14.3.3 Competitive Scoring Model
• 14.4 Forecasting Methodology
  • 14.4.1 Probability of Success Modeling
  • 14.4.2 Risk Adjustment Methodology
  • 14.4.3 Revenue Potential Modeling
  • 14.4.4 Scenario Planning Framework
• 14.5 Appendix
  • 14.5.1 Verified Emerging Therapy Inventory
  • 14.5.2 Clinical Trial Database
  • 14.5.3 Mechanism Benchmark Tables
  • 14.5.4 Regulatory Designation Summary
  • 14.5.5 Competitive Benchmark Matrices
  • 14.5.6 Abbreviations and Definitions
  • 14.5.7 Source Validation Documentation